Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
FL.4.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.19NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
HK.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GR.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
GR.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.1.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
EG.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GJ.1.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
GJ.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.7NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.16.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.22.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.22.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FE.1.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FE.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBL.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBL.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.56NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.5.56NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.1.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FY.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.5NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.2.3.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.9.5NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.9.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FE.1.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FE.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.13NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.16.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FR.1.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FR.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FY.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.5.1.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
EG.5.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.3.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FY.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.12NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FL.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FR.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FR.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.16.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.4.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FL.4.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FR.1.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FR.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FU.2.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FU.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.10NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used